2 edition of Disease costing: in-patient vs. out-patient treatment of rheumatoid arthritis. found in the catalog.
Disease costing: in-patient vs. out-patient treatment of rheumatoid arthritis.
Harold Manfred Schroeder
Written in English
|The Physical Object|
|Number of Pages||153|
Objective: To quantify direct costs of medication and cost of illness (according to functional capacity) for patients with rheumatoid arthritis (RA) in Germany, allowing further use in a health economic evaluation of sequential therapy with disease-modifying antirheumatic drugs (DMARDs) in specialised, i.e. rheumatological, care in Germany. Design and setting: The analysis was conducted . The variables on the treatment in the dataset are grouped according to the relevant medical care: outpatient care, inpatient care, rehabilitation, medications. The study was designed from the point of view of a major German health insurance fund with nearly million covered lives (DAK) in
More than two-thirds of patients with rheumatoid arthritis (RA) who were previously naïve to biologic disease-modifying anti-rheumatic drugs had an inadequate response to their first biologic during 1 year of follow up, according to a Taiwanese study published April 6, , in PLOS One by Qiang Shi, PhD, and colleagues.. The researchers also showed that inadequate responders had . Abstract. Background Rheumatoid arthritis (RA) is a chronic, debilitating disease with a significant impact on workplace productivity.. Aim To perform a systematic review of studies of the relationship between RA and reduced workplace productivity.. Methods Screening of titles identified in bibliographic database searches resulted in 38 articles subject to systematic review.
Patients seeking spine care at ambulatory surgery centers (ASCs) should expect lower costs—but not lower quality—compared to an inpatient hospital setting. This was the finding from a literature review of the available studies on outpatient spine surgery safety. Context Recent reports suggest that rheumatoid arthritis (RA) may be a risk factor for venous thromboembolism (VTE), particularly in conjunction with hospitalization data to identify RA and VTE may identify patients when they are at elevated risk for other reasons, obscuring the incompletely understood underlying association between RA and VTE and leading to inappropriate.
Ships, boats and craft
Ancient Indian astronomy and cosmology
Nebraska: its people and culture
Cross-references within the Internal Revenue Code of 1954 as of January 1, 1981
study of the effects of diffusion and kinetics on the spatial distribution of products created by electron deposition
Our restless heart
interaction between monetary and fiscal policies : the Donald Gow Lecture =
Writing for Our Lives
Principles of Descartes Philosophy
The Hittite Dictionary of the Oriental Institute of the University of Chicago/Volume L-N
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-analysis. the overall costing methodology, and adjustment for inflation. White LA, Nelson DR, Chawla AJ, Johnston JA. Biologic disease-modifying drug treatment patterns and associate costs for patients with rheumatoid arthritis.
J Cited by: J.A. Singh, D.E. Furst, A. Bharat, et al update of the American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisCited by: 7.
Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA) are the most common inflammatory rheumatic diseases in ordinary outpatient clinics. In Norway the prevalence reported is % for RA [ 1 ], % for PsA [ 2 ] and % for ankylosing spondylitis (AS) [ 3 ].Cited by: In addition, those who would like to explore the practicalities of establishing a service involving complementary medicine will gain an understanding of the likely provider cost of complementary medicine appears to be most sensitive to the time spent with the patient by the doctor.
Harcourt Publishers Ltd INTRODUCTION Robbert A Cited by: Sensitivity analysis. In a sensitivity analysis, some critical component in the calculation is changed by a meaningful amount or varied from worst case to Cited by: G.
Kobelt, K. Eberhardt, P. GeborekTNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
This improvement in patient health status resulted in cumulative QALYs gained per patient tested over 10 years. et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.
Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on. Development of the average HAQ score in the Lund and ERAS cohorts. HAQ scores improved or remained stable in the first years after diagnosis and entry into the studies, probably illustrating the effect of the introduction of treatment.
To read the full-text of this research, you can request a copy directly from the authors. Background New strategies and options for the treatment of rheumatoid arthritis (RA) have evolved during the past decade. A study was undertaken to investigate to what extent this influenced daily rheumatological care and how this translates into clinical and patient-reported outcomes.
Methods Data from a total of 38 outpatients with RA enrolled in the National Database of the German. Objective: To assess the relative cost effectiveness of clinical nurse specialist care, inpatient team care, and day patient team care.
Methods: Incremental cost effectiveness analysis and cost utility analysis, alongside a prospective randomised controlled trial with two year follow up. Included were patients with rheumatoid arthritis (RA) with increasing difficulty in performing activities.
The results of the study indicate that the cost of treatment of a patient with rheumatoid arthritis was about US$ in Turkey and total cost of treating rheumatoid arthritis patients becomes. Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.
However, due to their high costs, considerable differences in their utilization exist across the world, even among the various European countries, with many countries restricting access despite professional. Part A covers services, procedures, and drugs you receive as an inpatient at a hospital.
For Rheumatoid Arthritis patients, this might include joint replacement surgery or treatment for other medical conditions that develop. Part B covers infusions, outpatient surgeries, physical therapy, and other treatments for Rheumatoid Arthritis.
But, you. Introduction. Treat-to-target (T2T) is the dominant treatment strategy for patients with rheumatoid arthritis (RA).It involves escalating the intensity of treatment with disease-modifying anti-rheumatic drugs (DMARDs) until the desired disease activity target is attained.
Background The past decades have seen rapid advances in the treatment of rheumatoid arthritis (RA). In particular, the introduction of biologic and targeted synthetic disease-modifying antirheumatic drugs have improved clinical outcomes and reconfigured traditional RA cost compositions.
Objectives To map the existing evidence concerning cost of illness of RA, as the treatment pathway evolves. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause.
The hallmark feature of this condition is persistent symmetric polyarthritis (synovitis) that affects the hands and feet, though any joint lined by a synovial membrane may be involved. Rheumatoid arthritis (RA) is estimated to affect roughly % of the adult population 1, or more than million US adults.
The age of onset is commonly in the 40s and most afflicted individuals require medical treatment for decades. Rheumatoid arthritis is a chronic disorder for which there is no known cure.
Fortunately in the last few years, a shift in strategy toward the earlier institution of disease modifying drugs and the availability of new classes of medications have greatly improved the outcomes that can be expected by most patients. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
Clin Ther. ;33(6): Crossref, Medline, Google Scholar: 2. Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology. Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that affects an estimated million patients in the United States.
1,2 It is characterized by inflammation of the synovial membranes, which causes joint swelling, stiffness, and tenderness, and leads to progressive erosion and destruction of cartilage and bone tissue in the affected joints.The role of exercise in the treatment of inflammatory arthritis.
Bull Rheum Dis 42(1), 6. Gerber L, Furst G, Shulman B, Smith C, Thornton B, Liang M, Cullen K, Stevens MB, Gilbert N. Patient education program to teach energy conservation behaviors to patients with rheumatoid arthritis: A pilot study.
Arch Phys Med Rehabil 68(7) Introduction. The natural course of rheumatoid arthritis (RA) is still considered to be progressive and destructive. Treatment of RA has experienced tremendous innovations over the past 20 years, including targeted therapeutic agents as well as novel treatment strategies with a defined target of remission or low disease activity.These strategies are already part of both the American College.